Podcasts about Cart

For Su, her “Open Carts” reveal a lot about her hopes, dreams and chronic weaknesses as a middle aged Auntie looking for a good night's sleep. Meanwhile, Ku is having full Army emotional climax as she steps into the world building wonder of BTS. Plus an epic family vacation that is a feast for all the senses!Su's (very open) Cart:Sleep Spray Chillhouse nail serum jelly like tint Holiday topSu's Add To Queue:Love TrappedThe Gentlemen: Season 2Being Worthy with Jada Pinkett SmithKu's 3 Nights in Denver:The Gaylord Rockies Resort Add to Cue: Casa Bonita Mi Amor! Casa Bonita We have a website! Sign up at ADDTOCART.WORLD to see what we're up to.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Scientists, Unedited, host Eirini Vamva, PhD, talks with Bruce Levine, PhD, about his personal life and career in cell therapy. Dr. Levine talks about finding his way into immunology, learning from pivotal mentors, and following the unexpected opportunities that led him to the forefront of cell therapy. He reflects on the patients who inspired his work and the teamwork behind major breakthroughs. He also shares the story behind a CAR-T song he helped write and talks about some of the things that make him who he is outside the lab, including cycling and his love of wildlife and dancing.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Glioblastoma remains one of the most aggressive and difficult-to-treat forms of brain cancer, with recurrence posing a significant challenge for patients and researchers alike. In this episode of Moving Medicine Forward, Jeremy Schrand sits down with Moya Daniels, Vice President, Head of Regulatory and QA at Optieum Biotechnologies, to discuss the company's novel CAR-T cell therapy program, OPTF01, and its potential to transform treatment for recurrent glioblastoma. Moya shares insights into the science behind targeting both tumor cells and the tumor microenvironment, the evolving landscape of cell and gene therapy, and how global collaboration is helping accelerate innovation for patients with serious diseases.  1:30 | Introducing Optieum and the science behind OPTF01 2:20 | The unmet need in glioblastoma and the challenge of recurrence 4:45 | How OPF-001 differs from other treatment approaches 6:00 | Japan's role in advancing cell and gene therapy innovation 7:20 | Global regulatory strategy and the future of regenerative medicine 8:30 | Lessons from the Asia-Pacific biotech landscape 10:30 | The importance of collaboration in early clinical development 13:00 | What successful biotech-CRO partnerships look like 16:00 | Upcoming milestones for Optieum and the future of CAR-T therapies 17:15 | Expanding cell therapy beyond oncology into broader disease areas 

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program:https://bit.ly/3TZSmufGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab's late-stage development; uniQure crashes after four-year data from its Huntington's disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

Dinheiro em Portugal: o brasileiro que não sabe disso deixa euro na mesa em cada compra, cada saque e cada passagem no cartão. Antes de embarcar, entenda os erros que custam caro — e o direito que quase ninguém usa na hora de ir embora.O QUE ESSE VÍDEO RESPONDE:▸ Existe um caixa eletrônico em zona turística que "rouba" o brasileiro sem ele perceber — você sabe reconhecer?▸ Cartão de crédito brasileiro, conta global ou dinheiro em espécie: qual sai mais barato em Portugal de verdade?▸ Quando a maquininha perguntar "euros ou reais?", qual resposta protege o seu bolso? (a maioria erra)▸ Aquele imposto de 23% que aparece em tudo que você compra — dá pra recuperar parte antes de voltar pro Brasil?▸ E, no fim, quem vai MORAR, estudar ou investir em Portugal: qual é o jeito certo de levar valores altos sem pagar caro nem ter dor de cabeça com a Receita.

Wild on 7th is back baby!  First episode of the 26-27 season, and it's clear, based on the run time of this episode clocking in over 2 hours, that the talent has alot to say.  Joe O'Donnell joins us to kick off the new season and the guys dive right in and come out swinging with their bold predictions on the year.  Kinger does a victory lap, but what do Joe and Cart's have to say about this?  Buckle up for a doozy, and stick around for a summer recap from the Wall of St.Paul, Mr. Jesper Wallstedt.  

Social drivers of health such as geographic distance, travel burden, or limited availability at specialized patient centers bar many eligible patients from receiving first-line, potentially curative therapies, including chimeric antigen receptor (CAR) T-cell therapy. Community cancer centers in particular often struggle to offer CAR T, due to the extensive resources required to safely maintain a CAR T program: emergency department access, intensive care unit resources, and inpatient admission availability. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Andrew Dalovisio, MD, Director of the Myeloma, Lymphoma, and Cellular Therapy Program at Mary Bird Perkins, about how his team successfully launched the first fully outpatient CAR T-cell therapy program for select blood cancers in the Baton Rouge region. For other community cancer centers interested in developing a similar program, Dr. Dalovisio stressed the importance of identifying both a physician and administrative champion to navigate the process in a dyad partnership. "Less than one in five patients who meet indications [for CAR T-cell therapy] even get a referral. We can talk about how wonderful all these medicines we have are, but if they're not getting to the patients that need them, [they're] not serving [their] purpose." – Andrew Dalovisio, MD Guest: Andrew Dalovisio, MD   Director, Myeloma, Lymphoma, and Cellular Therapy Program  Mary Bird Perkins Cancer Center  Baton Rouge, Louisiana Resources: ACCC 43rd National Oncology Conference 2026 ACCC Innovator Mary Bird Perkins Cancer Center Designing a Safe, Fully Outpatient CAR T-Cell Program in the Community CAR T-Cell Therapy Insights from the Field Rising to the Occasion: The Impact of Outpatient CAR T-Cell Therapy at the Froedtert & Medical College of Wisconsin Health Network  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates in these sectors have highlighted significant scientific advancements, regulatory milestones, and promising clinical trial results that could impact patient care and drug development. One of the standout developments is the FDA's approval of AbbVie's Juvmo, marking a new chapter in Parkinson's disease treatment. As the first selective D1/D5 receptor agonist, tavapadon offers a novel approach by targeting specific pathways involved in Parkinson's. This breakthrough underscores ongoing innovations in neuropharmacology aimed at enhancing symptom management and improving quality of life for patients with this debilitating condition. In parallel, Mirum Pharmaceuticals has also received FDA approval for Atebrioz, a small molecule targeting ALK2, specifically designed for fibrodysplasia ossificans progressiva (FOP), a rare musculoskeletal disorder. The Phase 2 data supporting Atebrioz's approval provides hope by inhibiting the aberrant bone growth associated with FOP. This development not only expands therapeutic options for rare diseases but also emphasizes the significance of targeted therapies in addressing specific genetic and molecular pathways implicated in disease pathology. The business landscape is reflecting a thriving scene with significant licensing deals and partnerships. Merck & Co.'s licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical KRAS inhibitor, involves an initial payment of $400 million and potential total payments exceeding $2 billion. This deal highlights ongoing efforts to target KRAS mutations, prevalent in various cancers and notoriously difficult to inhibit. These strategic collaborations underscore the value placed on innovative oncology therapeutics and early-stage assets with transformative potential. In clinical trials, Johnson & Johnson's Carvykti continues to demonstrate promising outcomes with five-year progression-free remission in relapsed or refractory multiple myeloma patients. This finding reinforces the efficacy of CAR-T cell therapies targeting BCMA, paving the way for long-term disease control in hematological malignancies. Adicet Bio's prula-cel achieving lupus remissions in over half of Phase 1 patients further exemplifies the potential of cell therapies, particularly those utilizing gamma delta T cells for autoimmune conditions. Advancements are also being observed in ophthalmology. Kodiak Sciences' Zenkuda demonstrated comparable efficacy to Regeneron's Eylea in Phase 3 trials for wet age-related macular degeneration, highlighting competitive strides in anti-VEGF monoclonal antibodies for eye diseases. However, not all developments are positive. Roche has halted the development of its anti-latent myostatin antibody emugrobart following a Phase 2 failure in obesity/overweight trials. This illustrates challenges in achieving efficacy with novel metabolic targets. In other significant industry news, Eli Lilly has announced an initiative to increase access to GLP-1 receptor agonists for diabetes and obesity in low- and middle-income countries. This strategy reflects a broader industry trend towards addressing global health inequities by ensuring that breakthrough therapies reach beyond affluent markets. Similarly, Eli Lilly is exploring new therapeutic horizons for its GLP-1/GIP receptor agonist beyond diabetes and weight management into areas like depression and alcohol use disorders. Meanwhile, BioNTech faces setbacks as it plans to close three sites in Germany following unsuccessful attempts to find buyers, affecting approximately 1,800 jobs. This development underscores the volatile nature of the biotech industry and highlights challenges companies face in maintaining operational sustainability amidst shifting market demands. Moreover, Merck & Co., alongside Daiichi Sankyo, has withdrawn their lung cancer antibody-drug conjugate filing after failing to meet FDA requirements for accelerated approval. This setback serves as a reminder of the stringent regulatory landscape companies must navigate when developing oncology therapies. Despite these challenges, companies like Ultragenyx continue to make strides with significant advancements like their recent FDA approval of Fayuvi for a rare childhood neurodegenerative disease. These scientific advancements underscore the pharmaceutical industry's commitment to innovation and expanding therapeutic frontiers. The implications for patient care are profound, offering new treatment paradigms across various diseases with unmet needs. As the industry continues to evolve, maintaining rigorous scientific inquiry and regulatory scrutiny will be essential in realizing these therapeutic potentials safely and effectively. Thank you for tuning into Pharma Daily where we keep you updated on the latest scientific advancements shaping healthcare globally. Join us next time as we continue to explore groundbreaking developments impacting patient care across the pharmaceutical landscape.Support the show

A rare sight on the podcast: a paper from the cutting edge of practice, with the novel use of CAR-T cells in treating neurological diseases. Editors Phil Smith and Geraint Fuller bring a selection of papers from the October 2026 issue of the journal to discuss. Returning to the more commonplace, they present a how-to on conversations around lower back pain. There's the editors' choice for the issue: a majestic paper on suspected encephalitis, as well as non-motor symptoms in Parkinson's, a review of the 2024 McDonald criteria for MS diagnosis, and pitfalls to avoid with oxygen desaturation. Read the issue: https://pn.bmj.com/content/26/5/413  Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. Production and editing by Brian O'Toole. Thank you for listening. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is currently experiencing a wave of transformative changes, from strategic corporate relocations and groundbreaking partnerships to pivotal regulatory approvals and promising clinical trial outcomes. Let's begin with a significant corporate strategy shift. Lundbeck has made the decision to relocate its U.S. headquarters to Boston. This move is strategically designed to establish a global innovation hub that enhances its capabilities in neuroscience and artificial intelligence. Boston's burgeoning status as a biotech innovation nexus makes it an attractive destination, offering access to a rich ecosystem of research institutions and technological expertise. Such an environment is crucial for facilitating advancements in neurological research, reflecting the city's growing influence in the biotech world. Turning to regulatory updates, Merck & Co. and Eisai have achieved a notable milestone with FDA approval for their combination therapy of Welireg (belzutifan) and Lenvima (lenvatinib) as a second-line treatment for clear cell renal cell carcinoma. This approval is particularly significant as it marks the introduction of the first HIF-2α inhibitor combined with a tyrosine kinase inhibitor, providing a novel therapeutic approach for patients who have limited options after initial therapies. The combination therapy exemplifies the promise of innovative treatments in oncology, broadening therapeutic landscapes and potentially improving patient outcomes. In business development news, Genentech has partnered with Earendil Labs in a groundbreaking agreement valued at over $1.5 billion to co-develop AI-driven bispecific antibodies for cancer treatment. This collaboration underscores the industry's shift towards harnessing artificial intelligence and machine learning to optimize drug discovery and development processes. By leveraging AI, this partnership aims to accelerate the creation of targeted therapies with enhanced efficacy, highlighting a transformative trend in the industry. Clinical trials continue to yield encouraging results. Johnson & Johnson and Legend Biotech's CAR-T therapy, Carvykti (cilta-cel), has demonstrated a five-year survival benefit in a Phase 2 study for multiple myeloma patients. This milestone emphasizes the long-term efficacy of CAR-T treatments in hematological malignancies, showcasing their potential to significantly extend patient survival rates. In parallel, Regenxbio has reported positive three-year durability data for its gene therapy candidate RGX-314 in non-proliferative diabetic retinopathy, signaling advancements in gene therapy delivery systems that could revolutionize treatments for chronic conditions. Financial activities within the sector also reflect robust investment trends. Sadarx Pharmaceuticals has raised $446 million through an IPO to advance its siRNA and complement-mediated disease pipelines, indicative of sustained investor interest in RNA-based therapeutics. Additionally, Kasvu Therapeutics secured €30 million in Series A funding to propel its neuroplastogen depression candidate KTX-0141 forward, highlighting a growing focus on mental health therapeutics. However, challenges persist amid these advancements. GSK faces scrutiny from the UK self-regulatory body over transparency issues related to vaccine compliance, while Eli Lilly received criticism concerning promotional language about Orforglipron GLP-1 press releases. These incidents underscore the necessity of ongoing regulatory vigilance to maintain industry standards. Overall, these developments reflect a dynamic landscape characterized by strategic realignments, pioneering scientific collaborations, and significant regulatory milestones. The integration of AI into drug development processes and continuous innovation in therapeutic modalities like CAR-T and gene therapies are poised to enhance patient care significantly. As companies navigate complex regulatory landscapes and foster strategic partnerships, these efforts collectively highlight the sector's commitment to addressing unmet medical needs through advanced science and technology. In summary, the pharmaceutical and biotech industries are poised at an exciting juncture where scientific innovation meets strategic business acumen. With each advancement comes the potential not only to enhance patient care but also to redefine healthcare paradigms globally. As these sectors continue to evolve, their contributions promise a future where biotechnology plays an increasingly pivotal role in improving quality of life worldwide. Thank you for tuning into Pharma Daily—your source for vital updates from the frontiers of pharmaceutical and biotech innovation. Stay informed and join us next time as we explore more breakthroughs shaping healthcare's future.Support the show

Confira os principais destaques do noticiário desta segunda-feira. Proibição da sobretaxa no cartão começa a valer a partir de outubro na Austrália. Australiano desaparece durante trilha solo em montanhas da América do Sul. Juros podem atingir maior nível em quase 15 anos na Austrália. Número de brasileiros aptos a votar no exterior chega a quase 1 milhão. Portugal debate mudanças nas regras de arrendamento.#sbsaudiopodcast

Ongeveer de helft van de uitbehandelde patiënten met agressieve lymfeklierkanker geneest na CAR-T-celtherapie. Een commerciële behandeling kost al snel meer dan 300.000 euro. Het LUMC opende op 24 september een eigen CAR-T-afdeling, met behandeling, onderzoek en een eigen productielab op korte afstand van elkaar. Toch blijft de standaardbehandeling voorlopig bij de farmaceut: het Leidse lab maakt vooral cellen voor nieuwe toepassingen die nog in onderzoek zijn. In deze aflevering van BNR Beter bespreekt Nina van den Dungen of academische productie CAR-T-celtherapie betaalbaarder en breder toepasbaar kan maken. Te gast zijn Joost Vermaat, internist-hematoloog in het LUMC, en Rosa de Groot, onderzoeker en hoofd van het celproductielab van de afdeling Hematologie van het LUMC. Vermaat legt uit hoe de behandeling werkt: afweercellen van de patiënt krijgen in het lab een nieuwe antenne waarmee ze kankercellen herkennen. CAR-T kwam tot nu toe pas aan het einde van het ziektetraject, maar schuift op naar de tweede lijn. Hij is open over de keerzijde: een storm van eiwitten met hoge koorts, neurologische bijwerkingen en soms een opname op de intensive care. Vorig jaar behandelde het LUMC 38 patiënten. De Groot beschrijft het productieproces in de cleanroom, een verdieping onder de afdeling, waar de cellen binnen een week klaar kunnen zijn. Waarom de therapie bij de een aanslaat en bij de ander niet, weet ook zij niet precies; patiënten bij wie het niet werkt lijken een uitgeput immuunsysteem te hebben. Ze werkt aan uitbreiding naar auto-immuunziekten, waarvoor het LUMC samen met Amsterdam UMC een klinische studie uitvoert, en naar kankersoorten met een andere oorsprong, zoals acute leukemie, longkanker en eierstokkanker. Verder gaat het over de afweging om patiënten met een kleine kans op genezing de behandeling niet te geven, over het overleg met het Zorginstituut over zinnige zorg en acceptabele vergoeding, en over de samenwerking tussen de Nederlandse academische centra. Over deze podcast BNR Beter is het wekelijkse programma van BNR Nieuwsradio over een toekomstbestendige zorgsector. Elke week bespreekt presentator Nina van den Dungen met zorgprofessionals, ondernemers en beleidsmakers hoe de Nederlandse zorg met technologie, innovatie, regelgeving en wetenschap beter kan worden. BNR Beter is elke maandag om 15:30 op de radio te beluisteren bij BNR Nieuwsradio, en vanaf dat moment ook als podcast via deze feed. Over de makers Nina van den Dungen (1987) is freelance journalist en als radio- en podcastpresentator al ruim 15 jaar verbonden aan BNR. Zo is ze regelmatig te horen als presentator van de nieuwsprogramma's in de ochtend- en avondspits en daarnaast presenteert ze wekelijks de beleggingspodcast Doorgelicht en BNR Beter over de zorgsector. Stijn Goossens (1996) is de redacteur van BNR Beter en plaatsvervangend presentator. Bij BNR houdt Stijn zich bezig met onderwerpen over tech, wetenschap en innovatie. Hij presenteert ook de podcast Op de zaak en test elke vrijdag een nieuw techproduct in de Ochtendspits op BNR. Hiervoor was Stijn werkzaam voor NTR Wetenschap en techplatform Bright.See omnystudio.com/listener for privacy information.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD negativity, cytokine release syndrome, ICANS, infections, and non-relapse mortality. To explore the findings, their potential clinical implications, and key limitations of these indirect comparisons, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

The guys sit down with a couple qualifiers from each series and discuss the upcoming World Finals! Hear an in depth analysis of the horses coming to display their talents in Kansas City!Thank you to our sponsors of Episode #159!Shipshewana Harness & Supplies Glenwood Snacks Pennwoods Equine Products INC. The Draft Horse Journal Summit Professional Services Do you have suggestions for future episodes? Do you have ideas of someone we should have join us? Please send us any comments or questions to the Rinehold Tack & Western Wear  mailbag, podcast@naclassicseries.com

This episode originally aired 9/10/2024Trailblazer and hip-hop sensation Eve Cooper is on the mic today to talk about her new memoir “Who's That Girl?” Ambitious and fearlessly determined, Eve recounts her rise to stardom and struggles in a male dominated industry – something the Aunties know well. She talks about trusting her instincts, working with people who have wronged you, and connects with Ku about her fertility journey. Then, they dive into her cart, and Eve shares why she loves a sea salt body scrub (but not in her ice cream.)Thank you to our sponsor Sans Savon - an eco friendly cleansing company. Use code ADDTOCART for 10% off the starter set and free shipping.We want to hear from you! Drop us a message on Speakpipe.Subscribe to the Add to Cart newsletter for juicy extras.Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. “Who's That Girl? A Memoir” is out September 17! The Yvonne Leon heart bracelet is a gorgeous twist on the classic bangleThe Jo Malone Wood Sage & Sea Salt Body & Hand Wash smells amazing We have a website! Sign up at ADDTOCART.WORLD to see what we're up to.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Brought to you by TogetherLetters & Edgewise!In this episode: META'S HARDWARE BLITZMeta Launches $1,299 VR Headset That Look Like Glasses to Rival Apple Vision ProMeta is trying VR glasses (again), this time with more IMAXMeta introduces camera-free AI glassesMeta's Muse Charm looks like a Tamagotchi, but it's tapping into a much newer trendWHO'S WATCHING (AND PRICING) YOUSeattle City Council votes to ban surveillance pricing in sale of groceriesIf Flock Wasn't Enough, Dallas' AI Cameras Are Scanning Homes From Garbage TrucksTrump urges renaming AI to 'super intelligence' in UN speechMONEY MOVES IN TECHLovable's annualized revenue crosses $600M as vibe coding takes offExclusive: Infillion acquires location data company FoursquareSCIENCE BREAKTHROUGHSAnthropic says its biology lab has already found something bigInjectable nanoparticles make blind retinas respond to light in preclinical studyPLANES AND BIG RIGSUS halts flights at busy East Coast airports, says fiber line cut at construction siteHere's the Tesla Semi... againWEIRD AND WACKYWhat to do when your Waymo holds up a Secret Service motorcadeVogue sent robots down the runway at Vogue World, and people were not impressedTech Rec:Sanjay - ZuckOff Adam - Instinct Find us here:sanjayparekh.com & adamjwalker.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of recent breakthroughs and strategic moves that are shaping the future of drug development and patient care. Eli Lilly has achieved a significant milestone with the FDA's approval of Onswik, a once-weekly insulin therapy for type 2 diabetes. This innovative treatment is set to revolutionize diabetes management by offering a more convenient regimen, which could improve patient compliance and outcomes. Supported by robust phase 3 clinical trial data, Onswik is a testament to the importance of protein therapies in tackling metabolic diseases, highlighting Eli Lilly's commitment to advancing diabetes care. Additionally, Eli Lilly's collaboration with InnoCare Pharma exemplifies the trend of strategic partnerships playing an increasingly crucial role in accelerating drug discovery and development, focusing on five unmet medical targets with substantial financial milestones. In oncology, Elevar Therapeutics has received FDA approval for Lirafugratinib, a small molecule FGFR inhibitor targeting FGFR2-altered cholangiocarcinoma. This approval is a beacon of hope for patients with this challenging cancer type, emphasizing the potential of personalized medicine approaches in oncology. In another significant development, Elevar Therapeutics' FDA approval for Lyrfigtu marks a notable achievement as the first novel cancer drug from a Korean company to enter the U.S. market. This milestone underscores the global expansion of drug development capabilities and highlights Asian biopharmaceutical companies' growing influence. Promising clinical trial results continue to emerge. Merck's Remigromig demonstrated efficacy in a phase 2b/3 trial for diabetic macular edema as a Wnt pathway agonist, offering a novel approach in ophthalmology that could expand treatment options beyond VEGF pathways. In autoimmune diseases, Kyverna Therapeutics reported durable efficacy and safety for Mivocabtagene autoleucel in phase 3 trials for stiff person syndrome. This progress showcases the potential of CAR-T cell therapies in areas beyond oncology. Funding activities also highlight the sector's dynamism, with companies like Basecamp Research and BigHat Biosciences securing significant investments to advance AI-driven drug discovery platforms. These initiatives underscore the growing integration of artificial intelligence and machine learning in biopharmaceutical research—innovations that promise to expedite the identification and optimization of therapeutic candidates. On the regulatory front, Grail's Galleri multi-cancer blood test received positive recommendations from an FDA advisory committee. This liquid biopsy diagnostic holds promise for early cancer detection and screening advancements in precision medicine strategies in oncology. However, not all news is positive; Acadia Pharmaceuticals faced setbacks as its phase 2 trial for Remlifanserin missed primary endpoints in Alzheimer's disease psychosis, illustrating the challenges inherent in neurological drug development. Industry dynamics are further illustrated by Boehringer Ingelheim's strategic decision to offload its Shanghai CDMO to RAAS Blood Products, reflecting ongoing localization trends within pharmaceutical manufacturing. Meanwhile, AstraZeneca's Breztri received its third asthma-related approval from the European Commission, reinforcing its commitment to expanding its respiratory portfolio across key geographies. Additionally, legal actions such as the Florida Attorney General's lawsuit against three drug manufacturers and PBMs over alleged insulin price inflation highlight ongoing concerns about drug pricing. These actions may prompt further scrutiny and potential regulatory reforms within the pharmaceutical supply chain. Agentic AI is emerging as a pivotal trend in clinical trials, offering new models for connecting workflows and accelerating trial execution—a crucial advancement amid increasing trial complexity. Collectively, these developments illustrate an industry characterized by scientific innovation, strategic alliances, and regulatory achievements—all aimed at improving patient care and expanding access to novel therapies. As technological innovations like AI reshape clinical trials and companies navigate complex regulatory landscapes, the potential for breakthroughs in drug development remains high. These trends have profound implications for patient outcomes and the future direction of pharmaceutical research and development. Stay tuned as we continue to bring you more updates on these exciting advancements in our next episode.Support the show

Professors Zahir Amoura and David Isenberg reflect with our host Dr Raquel Faria on the 15th Annual Lupus Academy Meeting in Bratislava. They discuss the debate over early biologic treatment and explore what biomarkers, CAR T-cell therapy, cardiovascular prevention and artificial intelligence could mean for more personalised lupus care.Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.

Have you ever walked into a store, grabbed a cart, and realized it wasn't yours? Or maybe you've gotten into a car, only to discover it belonged to someone else? Then this episode is perfect for you. See omnystudio.com/listener for privacy information.

Catching up with the Chat/Discord! What we DON'T know about our favorite college basketball teams! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! JOIN OUR DISCORD HERE: https://discord.gg/np8E3Mbwey The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma.   Join us as we explored: The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab The importance of TP53 testing in mantle cell lymphoma and the evolving role of BTK inhibitors in frontline treatment The role of CAR T-cell therapy and bispecific antibodies in the evolving lymphoma treatment landscape   This discussion provided practical insights into current treatment algorithms and emerging strategies for patients with follicular lymphoma and mantle cell lymphoma.   Whether you're a hematologist, oncologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in lymphoma care, this episode offers an expert perspective on the rapidly evolving treatment landscape.   If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Subscribe for more expert discussions on hematology, oncology, lymphoma, immunotherapy, cellular therapy, targeted therapy, and advances in cancer care. #FollicularLymphoma #MantleCellLymphoma #Lymphoma #Hematology #OncologyBrothers

Autoimmune conditions are complex and treating them requires a coordinated approach that improves health outcomes and affordability.On the newest Pharmacy Friends, listen to Horizon Blue Cross Blue Shield of New Jersey's Timothy O'Shea and Prime's Sneha Sharma discuss how integrating pharmacy and medical benefits reduces fragmented care and supports clinically appropriate treatment.What you'll hearHow biosimilars and optimized sites of care are improving access for patientsWhy connecting data can help improve treatment decisionsWhat payers should watch as new oral therapies and potential CAR T treatments reshape autoimmune care

In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.

Una conversación amplia, distendida y transversal sobre los temas de actualidad que nos preocupan y los que nos apasionan. Esos temas que no protagonizan las escaletas informativas pero sí las reuniones con nuestros amigos y familiares, tratados en una mesa coral con mirada periodística y una curiosidad permanente.

The world has gone mad because a certain NFL QB got injured and was carted to the locker room. Jeff Mans seems to be the only person defending this move and has decided to record this week's episode on a cart of his own. Mans shares his thoughts on the injuries to Caleb Williams, Jaxson Dart and Jayden Daniels this week and discusses how each team will handle the losses and what fantasy managers should do as well. Due to all of the injuries going into week three Jeff has updated his top 10 waiver wire targets of the week here as well and counts them down for us. Then, it is time to take a look at some of the biggest fantasy football disappointments over the first two weeks of the season. Mans dives deeper into the likes of Justin Herbert, Kenneth Gainwell, Mavin Harrison Jr. and Kyle Pitts and assigns each player a “worry-o-meter” number moving forward. As always Jeff shares his favorite bet for Thursday Night Football between the Falcons and Packers including a historic look at one player that always seems to dominate on Thursday's. Remember to share the show with a friend, hit the like, favorite, heart, thumbs up, subscribe, and comment buttons for this episode!

This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhibitor resistance and why BTK mutation testing matters, and how to sequence therapy now that BTK inhibitors and venetoclax have both moved into the frontline. From there we get into venetoclax retreatment, the pirtobrutinib data from BRUIN CLL-321 and the new BRUIN CLL-322 triplet trial, the real-world CAR T experience that is changing how we think about cell therapy in CLL, bispecific antibodies, and the emerging class of BTK degraders. As always, if you haven't heard the earlier episodes in this series, start there first.If you haven't done so, be sure to check out our original CLL Series and our CLL Updates Part I episode as this update will draw on concepts covered previously!**This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration.** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Catching up with the Chat/Discord! Isaac Trotter's positional archetype rankings draft! Predicting where the top 10 recruits go to college! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! JOIN OUR DISCORD HERE: https://discord.gg/np8E3Mbwey The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The video explores the Emilcin Incident, one of the most famous and puzzling alien abduction cases in Polish history. In 1978, a 71-year-old farmer named Jan Wolski claimed that while driving his horse and cart, he encountered two strange, green-faced beings in a meadow. According to his account, he was taken aboard a hovering, crystal-white craft where he underwent a superficial examination by the entities before being released.Key aspects of the incident include:The Witnesses: Jan Wolski was described by his community as an honest, reliable, and straight-talking man, which made his claims difficult for investigators to dismiss as hallucinations or lies.Physical Evidence: Following the event, locals discovered unusual trapezoidal footprints, flattened crops, and mysterious black feathers at the site, though these have remained a subject of intense debate.The Aftermath: The story triggered a massive surge in UFO reports across Poland throughout the late 1970s and 1980s.Beyond the possibility of an extraterrestrial encounter, the video delves into a complex conspiracy theory involving two rival ufologists, Blanania Bolar and Wil Zvonic. Researchers have suggested that the entire incident may have been a staged event or a psychological experiment gone wrong—a prank intended to humiliate a rival that spiraled out of control and gained a life of its own in the public imagination. Ultimately, the Emilcin Incident remains a testament to the power of belief and the mysterious intersection of human deception and the unexplained.Don't forget to like, subscribe, and hit the notification bell for more fascinating stories about conspiracies, the paranormal and the unexplained. For all references and music, visit https://www.mydarkpath.com/65-emilcinTimestamps0:00 - The Emilcin Incident Introduced 0:56 - Jan Wolski's Morning Departure 3:39 - First Sightings in the Meadow 5:56 - The Beings Approach the Cart 8:24 - The Hovering Craft Appears12:00 - First Close View of the UFO Structure18:04 - Examination and Strange Odor19:49 - Black Birds Inside the Craft 21:45 - Return From the Encounter 25:11 - Additional Witness Testimony Emerges Connect with usInstagram: @mydarkpathpodcast Twitter/X: @mfthomasauthor Email us: explore@mydarkpath.com Visit us: www.mydarkpath.com Subscribe: www.patreon.com/mydarkpath Disclaimer: All opinions and comments expressed in the 'Comments' section do not reflect the opinions of My Dark Path or Dark Media LLC. All opinions and comments should contribute to the dialog and learning. My Dark Path and Dark Media LLC do not condone written attacks, insults, racism, sexism, extremism, violence or otherwise questionable comments or material in the 'Comments' section and reserves the right to delete any comment violating this rule or to block any poster from the channel.

Randy and Abe breakdown the Rams' dominant victory over the Giants, highlighting Matthew Stafford's connection with his receivers and Sean McVay's coaching adjustments. They also analyze a wave of NFL news, including Michael Penix Jr. being named the Falcons' starter and the theatrical nature of Caleb Williams' recent injury exit. (00:01:00) Rams Dominate Giants Recap (00:04:26) League Wide Injury News (00:07:14) NFL Brazil Game Concerns (00:08:13) Caleb Williams Injury Reaction

Catching up with the Chat/Discord! Players with the most to prove as practice begins! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! JOIN OUR DISCORD HERE: https://discord.gg/np8E3Mbwey The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.   We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.   Key topics covered in this episode: Frontline treatment options for DLBCL The role of polatuzumab in early-stage disease Treatment paradigms for advanced-stage DLBCL CAR T-cell therapy: who should receive it and when The importance of community and tertiary care partnerships in improving patient access to innovative therapies   Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and share your thoughts in the comments! #DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week podcast, BioCentury's analysts examine momentum in the biotech IPO market.The team also unpacks fatal toxicities in Novartis' autoimmune CAR-T trials and what they reveal about manufacturing, dosing and immune biology risks across the modality. In Washington, Steve Usdin previews Heidi Overton's FDA Commissioner confirmation hearing and reports on the persistent uncertainty around pharma tariffs ahead of the Sept. 29 deadline.View full story: https://www.biocentury.com/article/660870#BiotechIPO #CARTCell #FDA #PharmaTariffs #DrugDevelopment0:00 Introduction02:15 Biotech IPO Market10:38 Autoimmune CAR-T Safety21:56 FDA Commissioner Hearing26:47 Pharma Tariff UncertaintyTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Joe and the crew react to Caleb Williams' over-the-top response to a hamstring injury during the Bears game. They also analyze the NFL's shift toward heavy personnel and power running while weighing in on Tua Tagovailoa's future after his latest injury setback. (00:01:00) Show Intro and Weather (00:02:26) Sabres Preseason Roundup (00:03:21) NFL Passing Trends Decline (00:18:17) Caleb Williams' Injury Reaction (00:22:01) Tua Tagovailoa Retirement Rumors

This month, the gals invite all-things-astrology expert Aliza Kelly to the show to discuss truck spills, drunken wasps, George Michael, sensual microbeads, timeless nerd love, middle school revenge, and an absolute gut punch of an obit. Tune in for the September episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

In this episode of “Ask the Expert," Krissy Dilger of SRNA spoke with Dr. Barbara Willekens of the University of Antwerp about CAR-T cell therapy, explaining it as genetically engineered T cells (autologous or allogeneic) designed to recognize targets like CD19 on B cells and destroy them [00:01:19]. Dr. Willekens reviewed CAR-T's development since the 1980s for blood cancers, its severe potential side effects, and why successes targeting B cells prompted exploration in autoimmune diseases, including emerging trials for NMOSD and MOGAD [00:04:25]. She described patient selection, the clinical-trial process, expected B-cell reconstitution in about three months, and risks [00:18:55]. Dr. Willekens discussed research questions, including blood-brain barrier interactions, alternative CAR delivery, and future directions comparing approaches, targets, scalability, and cost [00:31:24].Barbara M.P. Willekens, MD, PhD, is a neurologist and Clinical Head of Neurology for multiple sclerosis (MS) and other CNS neuroimmunological diseases at Antwerp University Hospital, Belgium, and an Assistant Professor of Neurology at the University of Antwerp. She is an expert in MS and rare neuroimmunological diseases. She founded the University Neuroimmunology Center Antwerp (UNiCA), a multidisciplinary center bringing together patient care, research and education, which has been recognized as a SRNA Center of Excellence for rare neuroimmune disorders. Her clinical and academic career has focused on translating advances in neuroscience and immunology into better treatments and care for people living with neuroinflammatory diseases.Dr. Willekens leads and contributes to research ranging from early-stage translational science to international clinical trials and real-world studies. Her work includes clinical and translational research into immune tolerance and cellular therapies such as tolerogenic dendritic cells and CAR-T cell therapy, as well as approaches aimed at promoting remyelination and neuroprotection in MS and developing biomarkers for more personalized care. She has been a principal investigator in multiple academic trials and industry-led clinical trials and has helped build international collaborations and registries that generate evidence to improve treatment and patient care. Dr. Willekens plays a leadership role in the wider neuroimmunology community: she is Co-chair of the European Academy of Neurology's Coordinating Panel for Translational Neurology and Neuroscience, has previously served as Co-chair of its Scientific Panel for Neuroimmunology, is a member of the MSBase Scientific Leadership Group, of MOGAD Eugen Devic European Network, and is a driving force behind the International Susac Syndrome Consortium. Her leadership reflects a commitment not only to advancing science, but also to bringing researchers, clinicians and patients together to turn scientific progress into meaningful improvements in everyday care.00:00 Welcome and Guest Intro01:19 CAR-T Explained Simply04:25 From Cancer to Autoimmunity06:35 Why NMOSD and MOGAD10:58 B Cells and Targets15:56 One Time Treatment Question18:55 Who Should Get CAR-T21:46 What Patients Experience26:12 Immune Reset and Side Effects31:24 Dr. Willekens' Lab Research35:01 Next Steps and Open Questions36:24 Future CAR-T Approaches40:12 Closing Thoughts

In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, clinical pharmacy specialist with Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD Anderson Cancer Center and current ASTCT director of pharmacists (ex-officio) and Mark Hamilton, MD, of The University of Texas MD Anderson Cancer Center discuss immune effector cell-associated enterocolitis (IEC-EC), a rare but potentially severe late complication of BCMA-directed CAR T-cell therapy. As the use of CAR T-cell therapies continues to expand, understanding and managing delayed toxicities has become increasingly important.The discussion highlights:The clinical presentation, incidence, and risk factors associated with IEC-EC.Current approaches to diagnosis, including endoscopy, pathology evaluation, and detection of CAR T-cell infiltration in the gastrointestinal tract.Emerging insights into the biology of IEC-EC and the role of persistent CAR T cells.Treatment strategies, supportive care considerations, and areas of ongoing research.This episode provides valuable clinical and translational perspectives on a rare but important CAR T-cell-related toxicity and explores how ongoing research may help improve diagnosis, management, and patient outcomes.Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.This episode was made possible through support from Johnson & Johnson.

At the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, CancerNetwork® sat down with a variety of experts to discuss the latest data and emerging trends surrounding the management of different hematologic malignancies. Speakers and presentations covered everything from second primary malignancy risks to novel clinical trial findings across lymphoma, myelodysplastic syndrome (MDS), leukemia, and other patient patients.First, Jasmine M, Zain, MD, an attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center, highlighted key takeaways from her presentation exploring the risk of secondary lymphoma malignancies following CAR T-cell therapy. In addition to discussing the incidence, mechanisms, and possible risk factors of these second malignancies, she detailed how to clinically differentiate between malignancies directly driven by retroviral or lentiviral insertional mutagenesis compared with those arising from cumulative genotoxic stress.Additionally, David Sallman, MD, an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, reviewed findings from the phase 2a HT-6184-MDS-001 trial (NCT07052006). In this study, Sallman and colleagues assessed ofirnoflast (HT-6184), a first-in-class oral allosteric NEK7 inhibitor designed to block NLRP3 inflammasome activation, in patients with lower-risk MDS who were refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents. Sallman discussed the platelet and neutrophil responses observed with ofirnoflast and how its intermittent, oral dosing schedule may protect long-term quality of life, especially among older patients with comorbidities.Finally, Julie M. Vose, MD, MBA, the George and Peggy Payne Distinguished Chair of Oncology, professor in the Division of Hematology, and director of the Lymphoma Research Group at the University of Nebraska Medical Center, and co–editor in chief of ONCOLOGY®, spoke about general developments relating to the ever-evolving chronic lymphocytic leukemia (CLL) field. She detailed how minimal residual disease (MRD) testing may serve as an informative clinical decision-making tool, outlined strategies for community practices to keep up to date with the latest happenings in the space, and identified time-limited therapies as a key theme from the meeting.References Zain JM. Understanding the risk of second malignancies after CAR T therapies. Presented at: Society of Hematologic Oncology Annual Meeting; September 9-12, 2026; Houston, TX. Sallman D, Bafna V, Nath UK, et al. Ofirnoflast (HT-6184), a first-in-class allosteric NEK7 inhibitor, achieves durable transfusion independence (TI) and hematological improvement-erythroid (HI-E) in ESA-refractory lower-risk myelodysplastic syndrome (LR-MDS): phase 2 final results. Presented at: 2026 SOHO Annual Meeting; September 9-12, 2026; Houston, TX.

Chicago Bears quarterback Caleb Williams left Sunday's home-opener against the Minnesota Vikings on a cart after he injured himself in the fourth quarter.Become a supporter of this podcast: https://www.spreaker.com/podcast/shaw-local-s-bears-insider-podcast--3098936/support.This episode includes AI-generated content.

We've drilled into every corner of ecommerce on the show, but never the cart. Sylvie Wilson is here to fix that.After running two ecommerce businesses of her own, she built Unicorn Cart to solve a gift-with-purchase headache, and it's now used by 400+ brands. Her core message: the cart is the billboard everyone's neglecting, and it's a real part of your CRO strategy, not just a step to checkout. She's clear she's not here to sell Unicorn, just to share tactics and real A/B test data.In this episode:The cart is high-intent real estate most brands waste, optimise it for both AOV and conversionNever set and forget, one brand's $99 gift threshold beat $120 with a 64% higher AOVMake gifts something people actually want, keep the UX clean, and don't train customers to wait for a discountConnect with Sylvie Wilson Explore Unicorn CartSubscribe to the Add To Cart newsletter  SMS us to Suggest a Guest Connect with Nathan Bush Join the Add To Cart Community 

Mike Fong loves poker and playing the odds. Doctors gave him a 60% chance of surviving lymphoma that returned after four years cancer-free. Still, Mike is hopeful after joining a new CAR T clinical trial called "Triple Threat" that targets three of the most common cancer mutations.

Mike Fong loves poker and playing the odds. Doctors gave him a 60% chance of surviving lymphoma that returned after four years cancer-free. Still, Mike is hopeful after joining a new CAR T clinical trial called "Triple Threat" that targets three of the most common cancer mutations.

La dream team réagit à un sonore ou une déclaration forte de la part d'un joueur, entraîneur, président, légende du foot.

This week's Sister Solo is a full life update. We're getting into why the lack of an AM/PM routine is genuinely messing with us right now, coming out of seasonal depression, why dating is HARD, and the very real struggle of feeling like two different people depending on whether we're at work or at home (if you know, you know).We're also breaking down what's actually worth your attention in wellness right now — a new peanut butter ice cream for bears launch we can't stop talking about, AG1's new gummies, gluten-free Goldfish, a major acquisition in the better-for-you snack space, a beverage brand leaving the market, an electrolyte launch worth knowing about, and a wild new wearable that tracks blood flow to your head.Plus, Practitioner's Corner — why water quality actually matters and what we look for in a filter — and our current favorites, all linked for you to shop.Here's what we get into:Why we desperately need an AM/PM routineComing out of seasonal depressionDating is HARDThe Hannah Montana of it all: feeling like two different people at work vs. at homeOur Dancing With the Stars hot takesICFB's new peanut butter launchAG1 gummiesGluten-free GoldfishPurely Elizabeth's acquisitionUnwell Beverages leaving the marketTruvani's new electrolytes with monk fruit sweetenerLumia — the earrings that track blood flow to your headPractitioner's Corner: why water quality matters (and what we use)Current favorites — all linked on our ShopMyShop our current favorites: https://shopmy.us/shop/jillandjenna?tab=collections&Section_id=1016140Connect with us:Follow us on Instagram: @guttalkpodcastEPSIODE SPONSOR:FARMER FOCUS: https://www.farmerfocus.com/store-locator/

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York.Their discussion centered on the rapidly evolving treatment landscape for B-cell non-Hodgkin lymphomas, highlighting a wave of recent advances across frontline and relapsed diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) management. Drs Park and Brody framed this current era as one of unusually fast progress after decades of failed attempts to improve upon R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone).A major focus was the phase 3 frontMIND trial (NCT04824092), which added tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid) to R-CHOP in patients with frontline DLBCL. Dr Brody discussed the significant progression-free survival benefit with the experimental combination that extended across patient subgroups rather than being confined to patients with activated B-cell–like or non–germinal center disease, with only a modest increase in the rate of high-grade febrile neutropenia. He contextualized this against earlier trials in the DLBCL space.The discussion then turned to relapsed disease, where Dr Brody described the benefits of CAR T-cell therapy over stem cell transplant and reviewed bispecific antibody/chemotherapy combinations, including glofitamab-gxbm (Columvi) and epcoritamab-bysp (Epkinly) plus gemcitabine and oxaliplatin. He also emphasized the importance of clinical trials.Drs Park and Brody also explored the evolving MCL treatment paradigm, highlighting glofitamab's complete remission rate and the FDA approval of the BCL-2 inhibitor sonrotoclax (Beqalzi), alongside strategies to mitigate cytokine release syndrome and tumor lysis syndrome. The conversation concluded with a look at emerging therapies, including CD19-directed bispecific antibodies and in vivo CAR T-cell therapy delivered via viral and mRNA lipid nanoparticle vectors.

You're at the end of your launch, the cart is about to close… and you haven't hit your sales goal. Cue the spiral, right? In this episode, I'm walking you through exactly what to do in the final 24–48 hours of cart close so you can stop freaking out and actually maximize the momentum you've already built. We're talking: The one "lazy girl" move that will close more sales than anything else (and almost no one does it) Why your audience is not ignoring you — they're just busy, human, and waiting for a clear deadline How to send "last call" emails and posts that feel clean, honest, and non-manipulative Practical ways to invite DMs, questions, and conversations so buyers can finally get out of their heads and into a decision What to do after cart close — extending, sneaking people in, downsells, upsells, and how to do it in integrity The real work of launch season: managing your emotions, disappointment, and attachment without abandoning your people or your vision If you're in a launch right now (or ever plan to do one again), this episode will help you stop making yourself wrong, normalize the chaos, and make it way easier (and more profitable) to sell at the end. Hit play and let's turn your "oh fuck" cart close energy into "of course this sold" energy.

Chaque jour, en quelques minutes, un résumé de l'actualité culturelle. Rapide, facile, accessible.**

https://linktr.ee/FromBehindTheBarcast

Catching up with the Chat/Discord! The 10 most important players in college basketball! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! JOIN OUR DISCORD HERE: https://discord.gg/np8E3Mbwey The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A treatment exists that can cure aggressive lymphoma after chemotherapy has failed. Only about two in ten eligible patients receive it. Manali Kamdar is clinical director of lymphoma services at the University of Colorado Anschutz, and Paolo Strati is an associate professor of lymphoma and myeloma at MD Anderson Cancer Center. This episode is based on their article "CAR-T therapy can cure cancer. Why is it so underused?" published on KevinMD. You will hear what this therapy asks of a patient, from cell collection through the wait for manufacturing to the weeks spent living near a treatment center. They walk through the barriers a stakeholder summit identified, including the two-week payer authorization that runs while the cancer grows, the small number of accredited centers, and the myth that eligibility works like transplant eligibility. Press play to hear why they say a relapse should trigger a referral, and why they measure success by who can deliver this treatment rather than who receives it. This episode is brought to you by ModMed. Welcome to your new AI-Powered Practice from ModMed. We're transforming specialty care by embedding AI Assistants across your entire workflow. Our all-in-one platform of EHR, patient engagement, practice management, and RCM helps reduce repetitive work while keeping you firmly in control. Trained on de-identified data from nearly a billion patient encounters, this isn't just smarter software. It's a new way of working for specialty medicine, more efficient and more connected to the patient experience. Start building your AI-Powered Practice at modmed.com. VISIT SPONSOR → https://www.modmed.com/ SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast